TR EN AR RU KK

VEEVVeeva Systems Inc.

🇺🇸 US
Smart Money 56
305.55
USD
Analysis Scores
Lothien Robustness Score?
-
Neden bu skor?
Damodaran ?
-
Dalio Risk ?
-
Piotroski ?
4/9
Neutral
Previous period ROA data missing (C1 delta-ROA); Previous year data missing → margin comparison unavailable (C8)
Graham ?
$80.5
Pahalı
Lothien Robustness Summary
71/100
Lothien Sağlamlık: Güçlü (71/100)
Genel tablo olumlu. Finansal yapı sağlam, bazı riskler mevcut. | Kısa Vade: Olumlu | Uzun Vade: Nötr | Pozitif: 7 | Negatif: 3 | Nötr: 2
Net Kâr Pozitif
Son çeyrekte $273M net kâr açıklandı. Şirket kârlı.
Kâr Stabil
Net kâr bir önceki çeyreğe göre fazla değişmedi (%+4.8). İstikrarlı seyir.
Yıllık Kâr Büyümesi Güçlü
Geçen yılın aynı dönemine göre net kâr %+36.5 arttı. Büyüme trendi sağlıklı.
4 Çeyrek Üst Üste Artış
Son 4 çeyrek üst üste kâr artıyor. Güçlü yukarı trend devam ediyor.
Yüksek Net Kâr Marjı
Net kâr marjı %29.5. Her 100$ satıştan 29$ kâr kalıyor.
Net Nakit Pozisyonu
Şirketin nakdi borçlarından $1.7B fazla. Borç riski düşük.
Güçlü Likidite
Cari oran 5.46x — kısa vadeli borçları rahat karşılıyor.
Borç Hızla Artıyor
Toplam borç çeyreklik %+47.2 arttı. Finansman maliyetleri yükselir.
Güçlü Nakit Üretimi
Serbest nakit akışı ($239M) kârın %87'sini nakit olarak üretiyor. Kâr kalitesi yüksek.
Yüksek F/K Uyarısı
Trailing F/K: 46.4. Piyasa yüksek büyüme bekliyor ya da hisse pahalı. Büyüme gerçekleşmezse düşüş riski yüksek.
Yüksek PD/DD
PD/DD: 6.68. Piyasa defter değerinin çok üstünde fiyatlıyor. Büyüme beklentisi primli.
Yüksek EV/EBITDA
EV/EBITDA: 44.6. Pahalı değerleme.

Data date date not measured Not investment advice; the figures are rule-based model output. How the scores are computed

Score record
Method How the scores are computed · Scorecard
Data date date not measured
Update frequency Scheduled analysis run on business days at 19:30 Istanbul time; not every symbol is refreshed in every run

Method summaryThe Lothien Robustness Score (0-100) is a weighted combination of sub-scores computed by fixed rules from published financial statements and price data (Damodaran valuation, Dalio risk, Piotroski F-score, earnings quality, momentum and others). The rules are applied automatically to every covered stock, with weights that vary by sector.

AssumptionsCalculations rest on the company's latest published financial statements and on price data that may be delayed. Where four quarters have not been published, annual figures may be scaled from the available quarters. Model parameters such as the risk-free rate, the risk premium and long-term growth are fixed assumptions per exchange and contain no company-specific expectation.

Conflict of interestNo statement has been published on whether MIDAK, the operator of Lothien, or its team hold positions in these stocks. The figures are produced automatically by the same rules, without regard to any such position.

WarningThis information is not within the scope of investment advisory services and is not investment advice. The figures are the output of rule-based models and may not suit your financial situation or your risk and return preferences. Making an investment decision on the basis of this information alone may not lead to results that meet your expectations.

Model output; not investment advice; different models can disagree. Report an error

Risk Analysis (VaR) Yüksek
252 days
Annual Volatility ?
%43.2
VaR 95% ?
%4.42
daily max loss
VaR 99% ?
%6.28
daily max loss
CVaR 95% ?
%5.18
expected loss (tail)
Max Drawdown ?
%49.4
11.11.2025 → 10.04.2026
Skewness ?
0.91
Parametrik%4.42
Historik%3.70
Cornish-Fisher%3.42
Return Distribution
Valuation
Potential?
-
Balance Sheet Analysis? Q2026/9
Son 4 çeyrek ardışık kâr
Fiyat TRAMA-99 üzerinde: %+7.2 — teknik trend olumlu
Destek seviyesi: TRAMA-99 = 284.98 USD
Fundamental & Technical Analysis
Profitability
Net Profit Margin %29.5
Net profit margin %29.5 — very strong. Compared to previous quarter -0.1 point decrease.
ROE - Return on Equity (TTM) %7.3
ROE %7.3 — low return on equity.
EBITDA Margin %30.8
EBITDA margin %30.8 — operationally very efficient.
Gross Profit Margin %75.0
Gross profit per revenue %75.0. Strong pricing power.
Free Cash Flow Margin (TTM) %48.2
TTM Free Cash Flow is %48.2'i. Strong FCF generation — profit quality is high.
Valuation
P/E Ratio 46.4x Sector: 26.3x
F/K 46.4x — sector median's (26.3x) %76 above. Expensive zone.
P/B Ratio 6.68x Sector: 4.55x
PD/DD 6.68x — sector median's (4.55x) %47 above.
EV/EBITDA 44.6x Sector: 15.6x
EV/EBITDA 44.6x — sector median's (15.6x) %185 above. Expensive relative to EBITDA.
Indebtedness
Current Ratio 5.46x
Current ratio 5.46x — current assets are 2x short-term liabilities. Very healthy liquidity.
Net Debt / EBITDA 0.1x
Net Debt/EBITDA 0.1x — very low debt burden. Company can repay debt quickly.
Debt / Equity 0.02x
Low leverage — majority of assets financed by equity.
Interest Coverage 109.1x
Interest coverage 109.1x — very wide margin for paying interest expenses.
Growth
Revenue Growth (YoY) %+17.6
Revenue YoY %17.6 grew — healthy growth rate.
Net Profit Growth (YoY) %+36.5
Net profit YoY %36.5 increased — strong profit growth.
Score Explanations
Lothien Robustness
-
Moderate robustness (46/100). Valuation and risk criteria give mixed signals. Detailed review recommended.
Potential
-
Minus %33.2 expected value (204.69) vs current price comparison. 4/4 valuation models could be calculated. Model confidence %75.
Components: PE target: 172.42 | P/B target: 216.88 | EV/EBITDA target: 107.42 | DCF target: 189.94
Damodaran Valuation
-
Low Damodaran score (38/100). DCF analysis does not support current price.
Weak
Dalio Risk Analysis
-
Low debt risk (98/100). Interest coverage ratio 109.1x — strong. Debt/EBITDA 0.1x — in healthy range.
Leverage: 99/100 | Debt Service: 100/100 | Quality: 91/100
ROIC - Return on Capital
%14.0
ROIC (%14.0) slightly exceeds cost of capital (3.7 points).
WACC: %10.3
DCF Discounted Cash Flow
189.94
DCF (189.94) current price %38.0 below — cash flows do not support current price.
Current price: 306.40
Debt Cycle Phase
Early Expansion
Debt decreasing, growth gaining momentum. Company in balance sheet cleanup phase.
Piotroski F-Score
4/9
Weak Piotroski (4/9). Many balance sheet quality criteria not met. Note: Previous period ROA data missing (C1 delta-ROA); Previous year data missing → margin comparison unavailable (C8)
Neutral
Graham Intrinsic Value
$80.5
Expensive
⚖️ Sector Comparison
P/E Ratio
46.4x vs 26.3x
Sector median's %76 above — expensive
P/B Ratio
6.68x vs 4.55x
Compared to sector %47 more expensive (by book value)
EV/EBITDA
44.6x vs 15.6x
Compared to sector %185 higher EV/EBITDA
ROIC vs WACC
%14.0 vs %10.3 WACC
ROIC 3.7 bps above cost of capital
Net Profit Margin (TTM)
%29.3 vs %31.1 EBITDA margin
TTM net profit margin %29.3
TRAMA-99 Trend — Uptrend
Price (305.55), TRAMA-99 line's %7.2 above. Uptrend ongoing; monitor for TRAMA approach for trend change.
Price:: 305.55
TRAMA: 284.98
Difference: %+7.2
Charts
Indicators
BB deviation ?
RSI thresholds ?

Price Chart ?
▲ içeriden alım · ▼ içeriden satım · ★ katalizör (haber-sezgisel) · ■ 13D aktivist · ■ 13G pasif — SEC Form 4 ~2 gün gecikmeli, yalnız yönetici/direktör/%10+ sahip; katalizör = haber-sezgisel; 13D/G = %5+ pay bildirimi ~5 iş günü gecikmeli.
RSI (14) ?
Bollinger Bands ?
MACD ?
Gold-Based Price + TRAMA (Stock / Gram Gold) ?
Kurumsal Holdings — 13F (çeyreklik) ?

İçeriden Alım-Satım Akışı

Kim aldı, kim sattı, ne kadar

VEEV — Participation Finance Compliance
Loading…
The Lothien health scores and analyses on this page are for informational purposes only. They do not constitute investment advice. Please consult a licensed investment advisor before making investment decisions.